The Lessons from Angelman Syndrome for Research and Management by Pelc, Karine et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






The Lessons from Angelman Syndrome 
for Research and Management  
Karine Pelc, Guy Cheron and Bernard Dan 
Free University of Brussels 
Belgium 
1. Introduction 
Interest in monogenic disorders with epilepsy has provided significant insights into the 
pathophysiology of epilepsy. Among these disorders, Angelman syndrome has attracted 
particular attention because of its complex genetics. Angelman syndrome is characterized by 
developmental delay, absence of speech, motor impairment, epilepsy and a peculiar 
behavioral phenotype with apparent happy demeanor. It is caused by the lack of expression 
of the UBE3A gene, which can result from various abnormalities of chromosome 15q11-q13 
if they concern the chromosome inherited from the mother (illustrating the phenomenon of 
genomic imprinting). In most case, Angelman syndrome is due to a de novo 15q11-q13 
deletion. Rarely, patients have inherited both copies of chromosome 15 from the father and 
none from the mother, i.e. paternal uniparental disomy. As a result, no functional copy of 
the UBE3A gene is inherited from the mother. Patients with uniparental disomy have a 
statistically less severe phenotype than those with a deletion. Another small group of 
patients have an imprinting defect resulting in a lack of the typical maternal pattern of DNA 
methylation. Statistically, the phenotype of patients with an imprinting defect is 
indistinguishable form that of patients with uniparental disomy. In some patients, a 
mutation in the maternal UBE3A gene can be detected, and in about 10% of typical cases, no 
cytogenetic or molecular abnormality can currently be found. Patients with Angelman 
syndrome have a remarkably high risk of epilepsy compared to many other 
neurodevelopmental disorders. In particular, early-childhood onset of refractory epilepsy 
with atypical absences and myoclonic seizures with predisposition to developing non-
convulsive status epilepticus is a common presentation. In recent years, there has been 
increasing awareness of epilepsy in adults. The neurocognitive effects of seizures are 
difficult to evaluate. Propensity to develop epilepsy may be due to hypersynchronous 
neuronal activity, which might be related to abnormal GABA-mediated transmission due to 
lack of UBE3A expression, or other factors. Recent findings in animal models demonstrated 
altered dendritic spine formation as well as both synaptic [GABAA and NMDA 
transmission] and nonsynaptic (including gap junction) influences in various brain regions, 
including hippocampus and cerebellar cortex. Much research is still required to fully 
understand the functional links between lack of UBE3A expression and clinical 
manifestations of Angelman syndrome. Studies of regulation of UBE3A expression, 
including imprinting-related methylation, may point to possibilities of therapeutic 
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upregulation. Understanding relevant roles of the gene product might lead to targeted 
intervention. Further documentation of brain network dynamics, with particular emphasis 
on hippocampus, thalamocortical, and cerebellar networks is needed, including in a 
developmental perspective. There is also a need for further clinical research for improving 
management of problems such as epilepsy, behavior, communication, learning, motor 
impairment, and sleep disturbances.  
2. Clinical features 
The clinical picture of Angelman syndrome has been broadly documented, principally in 
children, but with an increasing emphasis on adolescents and adults. Clinical diagnosis is 
based on a set of physical (Fig. 1) and behavioral features (Williams et al., 2006) (Table 1). All 
patients have developmental delay with severely impaired cognitive skills. They show 
specific speech impairment; about one-third of patients speak no words at all, and the others 
rarely use more than five words. This contrasts with better receptive verbal communication 
and communication skills based on spontaneous or learned signs. Behavior is 
characteristically overactive, exuberant, sociable, and happy, with frequent smiling and 
laughing (Pelc et al., 2008a). Developmental motor impairment includes mild to moderate 
axial hypotonia, present from birth, and eventual spastic hypertonia of the limbs that may 
become apparent during the first year of life (Dan & Cheron, 2008). Despite varying degrees 
of ataxia, most patients develop independent walking. Gait is distinctive, with a wide 
support base, extension and lateral rotation of the lower limb, elbow flexion, and wrist 
supination. About 90% of patients have epileptic seizures. Seizure onset is often between 1 
and 3 years. Many seizure types, both generalized and focal, have been reported, including 
epileptic spasms, myoclonic absences, myoclonic, atonic, tonic, and tonic–clonic seizures, 
but atypical absence and myoclonic seizures have been particularly emphasized. As in other 
developmental conditions with epilepsy, the seizure disorder often improves in late 
childhood, although epilepsy can persist or reappear in adulthood, and be difficult to 
 
 
Fig. 1. Facial characteristics of a child with Angelman syndrome. Visual contact, fair eyes, 
midface hypoplasia, wide smiling mouth. 
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A. Consistent features (100%) 
Developmental delay, functionally severe. 
Movement or balance disorder, usually ataxia of gait, and/or tremulous movement of limbs. 
Movement disorder can be mild. May not appear as frank ataxia but can be forward 
lurching, unsteadiness, clumsiness, or quick, jerky motions 
Behavioral uniqueness: any combination of frequent laughter/smiling; apparent happy 
demeanor; easily excitable personality, often with uplifted hand-flapping, or waving 
movements; hypermotor behavior 
Speech impairment, none or minimal use of words; receptive and non-verbal 
communication skills higher than verbal ones 
 
B. Frequent features (more than 80%) 
Delayed, disproportionate growth in head circumference, usually resulting in microcephaly 
(-2 standard deviations of normal head circumference) by age 2 years. Microcephaly is more 
pronounced in those with 15q11.2-q13 deletions 
Seizures, onset usually before 3 years of age. Seizure severity usually decreases with age but 
the seizure disorder lasts throughout adulthood 
Abnormal electroencephalogram, with a characteristic pattern (Dan and Boyd 2003). The 
electroencephalographic abnormalities can occur in the first 2 years of life, can precede 
clinical features, and are often not correlated to clinical seizure events 
 




Tongue thrusting; suck/swallowing disorders 
Feeding problems and/or truncal hypotonia during infancy 
Prognathia 
Wide mouth, wide-spaced teeth 
Frequent drooling 
Excessive chewing/mouthing behaviors 
Strabismus 
Hypopigmented skin, light hair, and eye color compared to family, seen only in deletion 
cases 
Hyperactive lower extremity deep tendon reflexes 
Uplifted, flexed arm position especially during ambulation 
Wide-based gait with pronated or valgus-positioned ankles 
Increased sensitivity to heat 
Abnormal sleep-wake cycles and diminished need for sleep 
Attraction to/fascination with water; fascination with crinkly items such as certain papers 
and plastics 
Abnormal food related behaviors 
Obesity (in the older child) 
Scoliosis 
Constipation 
Table 1. Clinical diagnostic criteria for Angelman syndrome. (Adapted from Williams et al 
2006)  
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 control. Both convulsive and non-convulsive status epilepticus may occur. The latter 
isparticularly common during childhood, but it can occur in infancy and adulthood. In 
adolescents and adults, particularly, prolonged disabling tremor has been ascribed to 
cortical myoclonus (Guerrini et al., 1996) or myoclonic status (Ogawa et al., 1996; Elia, 2009). 
Piracetam, levetiracetam, topiramate and other antiepileptic drugs can be tried with variable 
results. The underlying mechanism remains unclear. It seems to be non-epileptic at least in 
some cases, where response to levodopa (Harbord, 2001) or reserpine (Stecker & Myers, 
2003) has been documented. Sleep problems commonly reduced total sleep time, increased 
sleep onset latency, disrupted sleep architecture with frequent nocturnal awakenings, 
reduced rapid eye movement (REM) sleep, and periodic leg movements. 
3. Natural history of the seizure disorder 
Onset of seizures is often before 3 years of age, mostly between 1 and 3 years (Buntinx et al., 
1995; Buoni et al., 1999; Clayton-Smith, 1993; Saitoh et al., 1994). Whereas epilepsy is often a 
prominent clinical problem in childhood, seizure onset occurs during infancy in a minority 
of patients. If seizures do occur in infants, they tend to do so in a febrile context. In a high 
proportion of patients, the onset of epilepsy precedes the diagnosis of Angelman syndrome 
(Valente et al., 2006). Seizure types may evolve with age (Matsumoto et al., 1992; Uemura et 
al., 2005). As in other developmental conditions with epilepsy, the seizure disorder often 
improves in late childhood. Sustained seizure-freedom following epilepsy in childhood has 
been found in four of five patients with a 15q11-q13 deletion followed up longitudinally 
until the age of 30 years or more (Uemura et al., 2005). Other studies, however, have shown 
that epilepsy can persist or reappear in adulthood (Moncla et al., 1999; Thomson et al., 2006).  
4. Seizure types 
Many different types of seizures have been reported, both generalized and focal. They 
include myoclonic absences, myoclonic, atonic, tonic and tonic—clonic seizures (Cersósimo 
et al., 2003; Elia et al., 1998; Galván-Manso et al., 2002; Laan et al., 1997; Matsumoto et al., 
1992; Minassian et al., 1998; Viani et al., 1995). Atypical absence and myoclonic seizures have 
been particularly emphasized. Multiple seizure types occur in about half of the patients with 
a 15q11-q13 deletion (Valente et al., 2006). Patterns of seizures, including type, age of onset, 
other clinical features and electroencephalographic features of patients with Angelman 
syndrome may show some resemblance with defined epileptic syndromes. In this context, it 
is important to characterise their epilepsy correctly given implications for both management 
and prognosis. Although epileptic spasms are the typical seizure type of West syndrome or 
infantile spasms (in association with hypsarrhythmic electrencephalogram and 
‘developmental arrest’), this epileptic syndrome has rarely been documented convincingly 
in Angelman syndrome. In the vast majority of cases, the electrencephalographic patterns 
seen in Angelman syndrome can be differentiated easily from hypsarrhythmia (Dan & Boyd, 
2003). The most commonly identified of these typical patterns consists of runs of rhythmic 
2—3/s activity of high amplitude often exceeding 300 mV seen mainly over the frontal 
regions (Boyd et al., 1988, 1997; Korff et al., 2005; Laan et al., 1997; Valente et al., 2003 ) i.e. 
Pattern I in Dan and Boyd’s classification (Dan & Boyd, 2003). Although tonic seizures and 
complex absences can occur in Angelman syndrome, confusion with Lennox-Gastaut 
syndrome can be avoided without much difficulty in many cases. Confusion with the 
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electroencephalographic features of Lennox- Gastaut syndrome has also arisen in some 
reports, although the runs of slow spike—wave complexes seen in Angelman syndrome are 
usually rhythmic and signal non-convulsive status epilepticus (which has no specific 
features and is indeed indistinguishable from that seen in Lennox-Gastaut). In contrast, 
another epileptic syndrome, referred to as myoclonic status in non-progressive 
encephalopathies, has been appropriately recognised in a number of patients with 
Angelman syndrome (Dalla Bernardina et al., 1995). This syndrome is characterised by 
recurrent episodes of myoclonic status in patients who have pre-existing non-progressive 
neurological deficits including severe intellectual disability, axial hypotonia and ataxia 
(Dalla Bernardina et al., as cited in Roger et al., 1983) It also occurs in Wolff-Hirschhorn 
syndrome (4p-syndrome), neonatal encephalopathy and metabolic disorders such as non-
ketotic hyperglycinaemia. Another condition, which is not an epileptic syndrome stricto 
sensu in the absence of seizures, is electric status epilepticus during sleep, also known as 
continuous spike—wave discharges during sleep. The electroencephalographic features 
consists of generalised slow (usually around 2/s) spike—wave complexes, sometimes with a 
frontal emphasis, occupying more than 85% of slow-wave sleep, while this activity is 
exceedingly rare in rapid eye movement sleep. When the triad of electroencephalographic 
continuous spike—wave discharges during sleep, seizures (all types can occur except for 
tonic seizures) and impairment of neuropsychological and motor (e.g. ataxia) function is 
present, the condition can be regarded as an epileptic syndrome termed ‘epilepsy with 
continuous spike—wave discharges during sleep’. This syndrome has rarely been 
documented in Angelman syndrome (Rubin et al., 1997). The lack of clinical alteration 
concomitant to the electrographic epileptiform activity excludes it from the context of non-
convulsive status epilepticus (Dan & Boyd, 2005). Both convulsive and non-convulsive 
status epilepticus may occur. Compared to other conditions with epilepsy, the latter is 
relatively common, including in cases that are not due to 15q11-q13 deletion (Boyd et al., 
1997; Laan et al., 1997; Uemura et al., 2005; Viani et al., 1995). Although non-convulsive 
status epilepticus appears to be more common during childhood, it can occur in infancy 
(Ogawa et al., 1996) and adulthood (Espay et al., 2005). Electroencephalogram shows 
continuous epileptic discharges which are distinct from the typical rhythmic 
electroencephalographic features of Angelman syndrome (Dan & Boyd, 2003). The 
distinction between generalised and complex partial non-convulsive status epilepticus is 
often difficult to make. The term ‘dialeptic status epilepticus’, which refers to seizure 
phenomenology with alteration of consciousness as main ictal feature without any reference 
to the origin, might appear more appropriate in this context (Dan & Boyd 2005). Frequent or 
prolonged episodes of dialeptic status epilepticus may contribute to a poor cognitive 
outcome, as suggested in other conditions with epilepsy (Hoffmann-Riem et al., 2000). In 
some cases, prolonged disabling tremor has been ascribed to cortical myoclonus (Guerrini et 
al., 1996) or myoclonic status (Ogawa et al., 1996). Such disabling resting tremor may appear 
in day-long clusters, particularly in adolescents or adults (Clayton-Smith, 2001; Van 
Buggenhout et al., 2000). When severe, it may result in loss of ability to eat or walk 
independently during episodes. The aetiology of this tremor remains unclear. It seems to be 
non-epileptic in a number of cases. In one report of two adult patients, associated cogwheel- 
type rigidity and bradykinesia suggested Parkinsonism and tremor improved dramatically 
on levodopa (Harbord, 2001). In another young adult, episodes of generalised shaking 
predominating in the upper extremities were correlated with 4—10/s electromyographic 
bursts but no ictal electroencephalographic changes (Stecker & Myers, 2003). The 
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electromyographic features were similar to the postural bursting activity described in 
children with Angelman syndrome (Dan & Cheron, 2004) although the latter was not 
associated with actual tremor. The muscle activity associated with the movements was so 
intense that it induced hyperthermia and rhabdomyolysis. The movements were effectively 
controlled by reserpine in association with topiramate. This prominent, quasi-clonic activity 
may be difficult to distinguish from myoclonus. In a few other cases, fast-bursting 
myoclonus has been correlated with electroencephalographic activity of similar frequency or 
at subharmonics, suggesting cortical myoclonus (Guerrini et al., 1996; Ogawa et al., 1996 ) 
similar to findings in Rett syndrome (Guerrini et al., 1998). Finally, it must be noted that 
absence of electroencephalographic discharges correlated with bouts of laughter suggests 
that they do not correspond to gelastic seizures. Other possibly challenging spells include 
stereotyped movements, tremors, staring episodes, eye rolling, motor/behavioural 
manifestations of gastro-oesophageal reflux (Sandifer syndrome) and self-gratification 
episodes (‘masturbation’). 
5. Management 
Seizures may be difficult to control with pharmacological treatment, particularly in 
childhood. Surveys of antiepileptic drugs used in patients with Angelman syndrome have 
suggested that sodium valproate is the most commonly used (Ruggieri & McShane, 1998). 
The use of clonazepam has also been reported in a number of cases. These drugs have been 
recommended on the basis of early reports of retrospective, open studies of limited patient 
series. The effectiveness of other benzodiazepines, such as nitrazepam and clobazam, seems 
to be similar to that of clonazepam in patients with Angelman syndrome (Østergaard & 
Balslev, 2001). However, in the majority of patients, the use of benzodiazepines does not 
appear to be justified as a first-line treatment. Phenobarbitone can be both effective and well 
tolerated in infants. Because of sedative or cognitive side effects, it is less used in children 
and older patients. However, Clayton-Smith and Laan have suggested that it may be a good 
option in adults (Clayton-Smith & Laan, 2003). Levetiracetam, topiramate, ethosuximide 
and lamotrigine have been successfully used in many cases, but there is a lack of controlled 
studies. It is noteworthy that although lamotrigine drug has no direct effect on GABAA 
receptors (Gibbs et al., 2002) it might promote GABRB3 gene expression in hippocampal 
cells (Dan et al, 2007). Some antiepileptic drugs may be paradoxically detrimental through 
increase in the risk of seizures, facilitation of the development of other seizure types or 
precipitation of non-convulsive status epilepticus. These drugs include carbamazepine 
(Minassian et al., 1998; Valente et al., 2006; Laan et al., 1996) oxcarbazepine (Valente et al., 
2006) vigabatrin (Kuenzle et al., 1998; Østergaard & Balslev, 2001; Valente et al., 2006) 
tiagabine and probably gabapentin. However, this observation does not imply absolute 
contraindication of these drugs, which may prove useful in some patients. This aggravation 
due to antiepileptic drugs is not specific to Angelman syndrome, where it appears to be 
more marginal than in some epileptic syndrome, notably idiopathic generalised epilepsies. 
Response of non-convulsive status epilepticus to treatment is variable and management 
may be difficult. Oral benzodiazepines, corticosteroids and ketamine (Mewasingh et al., 
2003) may be early options, but there has been a marked lack of well-designed studies. 
Morbidity associated with aggressive treatment mayoutweigh the risk of therapeutic 
abstention. In contrast, convulsive status epilepticus requires early effective treatment 
according to common treatment protocols. Non-pharmacological management is rarely 
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considered, despite the relatively high prevalence of drug resistance. Ketogenic diet was 
effective in four patients with refractory epilepsy in Valente et al.’s series (Valente et al., 
2006). 
6. Neurophysiologic features 
The contribution of EEG to diagnosis of Angelman syndrome has been recognized in both 
children (Boyd et al., 1988; Korff et al., 2005; Rubin et al., 1997) and adults (Sandanam et al., 
1997; Van Buggenhout et al., 2000), and particularly highlighted in infants (Van Lierde et al., 
1990). In contrast to the paucity of physiologic rhythms, interictal EEG shows three 
distinctive high-amplitude rhythmic patterns (Dan & Boyd, 2003), which can reinforce the 
clinical diagnosis (Williams et al., 2006). The most commonly identified EEG abnormality 
(pattern I) consists of runs of high amplitude rhythmic 2–3 Hz (delta) activity, seen mainly 
over the frontal regions (Fig. 2A). A variant composed of sharp slow waves (Fig. 2B) has 
been characterized as ‘‘triphasic’’ (Laan et al., 1997), ‘‘triphasic-like’’ (Valente et al., 2003), 
‘‘polyphasic slow waves’’ (Minassian et al., 1998), ‘‘pattern IB’’ (Dan & Boyd, 2003), or 
‘‘notched delta’’ (Korff et al., 2005). Another pattern consisting of prolonged runs of 
rhythmic 4–6 Hz (theta) activity with centrotemporal emphasis (pattern II, Fig. 2C) is 
common in young children (Rubin et al., 1997), but tends to disappear after 5 (Boyd et al., 
 
  
Fig. 2. Typical rhythmic electroencephalographic patterns. A, B. Pattern I: run of high-
amplitude delta activity mixedwith spikes predominating in the anterior regions without 
clinical correlation. C. Pattern II: run of diffuse moderate-amplitude theta activity. D. Pattern 
III: high amplitude delta activity mixed with spikes in the posterior regions on eye closure. 
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1988) to 12 (Laan et al., 1997) years of age. Pattern III consists of high amplitude 3–6/s 
rhythmic activity sometimes containing small spikes, predominating over posterior regions 
(Fig. 2D). Eye closure facilitates its occurrence (Boyd et al., 1988; Rubin et al., 1997; Viani et 
al., 1995). In addition to these characteristic rhythmic activities, electroencephalography 
(EEG) may show epileptic discharges. Interictal nonspecific discharges including spikes, 
spike-waves, polyspike-wave, and more rarely bursts of fast sharp activity (Cersósimo et al., 
2003) may show focal or generalized distribution. A few patients show prolonged runs of 2–
3 Hz spike-wave complexes without any clinical correlation (Dan et al., 2000; Matsumoto et 
al., 1992; Uemura et al., 2005). 
7. Genetic aspects 
In more than 90% of patients with a clinical diagnosis of Angelman syndrome, genetic 
testing can demonstrate a molecular mechanism causing lack of expression of the UBE3A 
gene. This gene is imprinted in (at least) some brain cells (Rougeulle et al., 1997), being 
expressed only from the chromosome 15 that is inherited from the mother. In about 70% of 
patients with Angelman syndrome, lack of UBE3A expression is due to microdeletion of the 
15q11-q13 region on the maternally inherited chromosome 15. Similar abnormalities 
affecting the paternally inherited chromosome 15 result in Prader-Willi syndrome, a 
clinically distinct condition (Knoll et al., 1989). This illustrates genomic imprinting, where 
expression of imprinted genes is effectively monoallelic and depends on the paternal or 
maternal origin. This nonmendelian type of inheritance in human disease also prevails in 
Huntington disease, Beckwith-Wiedemann syndrome, and Silver- Russell syndrome. Other 
genes are implicated in the deletion, possibly resulting in a contiguous gene syndrome. The 
ATP10C gene is expressed preferentially from the maternal chromosome only; lack of its 
expression may underlie eventual obesity (Meguro et al., 2001). ‘‘Pinkeyed dilution’’ or P 
gene has been implicated in hypopigmentation that is seen in patients with a 15q11-13 
microdeletion, characterized by light skin, reduced retinal pigment, low hair bulb tyrosinase 
activity, and incomplete melanosome melanization (King et al., 1993). Absence of a copy of 
the GABRB3, GABRG3, and GABRA5 genes, which code for subunits of GABAA receptor, 
has tentatively been related to abnormalities in GABAergic neurotransmission (Olsen & 
Avoli, 1997). There is a mutation in the maternal UBE3A gene (Kishino et al., 1997; Matsuura 
et al., 1997) in another 5–10% of patients (Lossie et al., 2001; Malzac et al., 1998). About 3–5% 
of patients have an imprinting defect resulting in lack of the typical maternal pattern of 
DNA methylation required for UBE3A expression (Buiting et al., 1995). Approximately 2–
3% of patients inherited both copies of chromosome 15 from the father and none from the 
mother, that is, paternal uniparental disomy (Malcolm et al., 1991); as a result, no functional 
copy of the UBE3A gene is inherited from the mother. Finally, 1–2% of patients have 
complex structural chromosome abnormalities leading to inactivation of the maternal 
UBE3A gene (Chan et al., 1993). To some extent, these molecular categories can be linked to 
two phenotypic pictures. One is more severe and seen in association with 15q11-q13 
microdeletion or UBE3A mutation, that is, with only one intact copy of the UBE3A gene, 
which does not bear a maternal methylation pattern. Patients in those groups tend to have 
more severe microcephaly, greater delay in developmental milestones, more severely 
impaired communication skills, more severe seizures, and show hypopigmentation (Bürger 
et al., 1996; Lossie et al., 2001; Minassian et al., 1998; Moncla et al., 1999). The other 
phenotypic picture is relatively less severe, with low incidence of microcephaly, of 
hypopigmentation, less severe seizures, and more words, although speech is extremely 
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limited and not used as a main communication tool. It is seen in association with 
uniparental disomy or imprinting defect, that is, with two intact copies of the UBE3A gene, 
none of which bear a maternal methylation pattern. However, the core phenotypic features, 
including the rhythmic EEG patterns described earlier, are shared, and there is much 
overlap in their severity across patients in all molecular classes. Genetic testing, therefore, 
has confirmatory rather than prognostic value. Nevertheless, obtaining a precise genetic 
diagnosis is essential in view of the complexity of genetic counseling. 
8. Animal models 
Molecular characterization of Angelman syndrome has allowed the development of animal 
models of the different mechanisms underlying the syndrome. Such models provide 
important insights into the pathophysiologic mechanisms involved in various aspects of 
Angelman syndrome. A mouse model of maternal microdeletion including the Ube3a gene 
did not result in obvious phenotypic abnormalities, but fine phenotypic aspects, such as 
motor control, learning skills, or neurophysiological features, have not been studied (Gabriel 
et al., 1999). This model is potentially very interesting, as it would represent the most 
prevalent situation in the human condition. The absence of a drastic phenotype, however, 
contrasts with Angelman syndrome. A model of Angelman syndrome due to paternal 
uniparental disomy showed high incidence of failure to thrive for the first 4–5 weeks and 
spontaneous death in the first month (Cattanach et al., 1997). Survivors developed obesity, 
hyperactive behavior, and gait described as ‘‘ataxic.’’ Electrocorticographic recordings 
showed bilateral prolonged runs of high-amplitude delta rhythmic activity. The phenotype 
of proposed models of imprinting defect (Wu et al., 2006) has not been studied in detail, but 
mice showed a marked decrease in Ube3a (the gene product) in both the cerebral cortex and 
cerebellum. Mice with selective maternal Ube3a gene inactivation, providing models of 
Angelman syndrome due to maternally-inherited UBE3A gene mutation, showed no 
obvious phenotypic abnormality, but fine testing revealed impaired motor coordination and 
learning (Jiang et al., 1998; Miura et al., 2002). One of these models showed context-
dependent learning impairment and deficits in hippocampal long-term potentiation 
(Weeber et al., 2003). These abnormalities have been related to diminished calcium/ 
calmodulin–dependent protein kinase II activity, which was secondary to altered 
autophosphorylation. More recently, van Woerden et al. demonstrated that loss of this self-
inhibition resulted in improvement of both learning defects and synaptic plasticity (van 
Woerden et al., 2007). This mouse model also showed abnormal dendritic spine 
development in hippocampal 
pyramidal neurons (Dindot et al., 2008). Electrocorticographic recordings showed almost 
continuous runs of rhythmic 3/s activity mixed with polyspikes and slow waves (Jiang et 
al., 1998). In another mouse model with targeted inactivation of maternal Ube3a (Miura 
et al., 2002), hippocampal electrocorticographic recordings showed runs of high amplitude 
4-5/s spike–waves. Intracerebellar recordings in alert mice showed local field potential high 
frequency (ca. 160 Hz) oscillation correlating with increased Purkinje cell firing rate and 
rhythmicity (Cheron et al., 2005, 2008).This oscillation was inhibited by gap junction, 
NMDA, or GABAA receptor blockers. In sleep, these mice showed reduced proportions of 
slowwave sleep (Colas et al., 2005). Among mouse models that do not involve Ube3a 
expression, the most relevant seems to be provided by mice that are deficient in the Gabrb3 
gene (Homanics et al., 1997). Surviving homozygous knockout mice had seizures, 
hyperactive behavior, coordination and learning impairment (DeLorey et al., 1998; 
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Homanics et al., 1997), reduced benzodiazepine binding to GABAA receptors in the cortex 
(Sinkkonen et al., 2003), and developmental changes in electrocorticographic recordings 
consisting of progressive slowing and subsequent appearance of highamplitude irregular 
slow and sharp waves, and generalized clonic seizures associated with spiking (DeLorey et 
al., 1998). In vitro electrophysiologic study suggested loss of reciprocal GABAergic 
inhibition between thalamic reticular neurons (Huntsman et al., 1999). Heterozygotes 
tended to show behaviors intermediate between wild-type and homozygous null mutants, 
with significant abnormalities in electrocorticography, seizures, and rest–activity patterns 
(DeLorey et al., 1998). This model shows interesting similarities with several phenotypic 
aspects of Angelman syndrome, mostly epilepsy. It has been particularly well studied from 
the neurophysiologic point of view. Recently, genetically engineered Drosophila with null 
Dube3a (UBE3A homolog) has been suggested as a model for Angelman syndrome (Wu et 
al., 2008). Mutants showed abnormal climbing behavior, impaired olfactory associative 
memory, and altered free-running circadian activity, which the authors tentatively related 
(in a somewhat far-fetched leap) with abnormal motor coordination, cognitive impairment, 
and sleep problems in patients with Angelman syndrome. Dube3a-null mutant flies also 
showed reduced dendritic branching of sensory neurons in the peripheral nervous system 
and altered growth of terminal dendritic processes (Lu et al., 2009). 
9. Pathophysiology 
Although the causative gene was identified more than 12 years ago (Kishino et al., 1997; 
Matsuura et al., 1997), underlying pathophysiology is still a matter of speculation. The gene 
product, UBE3A, acts as an E3 ubiquitin–protein ligase along the ubiquitin pathway. The 
best-characterized function of ubiquitination is to mark target proteins for specific 
proteolysis by proteasomes. Cytoplasmic accumulation of the p53 oncoprotein was found in 
Purkinje cells and in a subset of hippocampal neurons maternal Ube3a-deficient mice (Jiang 
et al., 1998). Because this protein is specifically ubiquitinated by UBE3A, the authors 
suggested that failure of Ube3a to ubiquitinate target proteins and promote their 
degradation could be a key aspect of the pathogenesis of Angelman syndrome. However, 
these findings have not been replicated in other models. Ubiquitin-mediated proteolysis 
may be important in a number of neuronal processes, including synaptogenesis and 
mechanisms of long-term memory. The ubiquitin pathway may also be involved in 
regulating abundance of postsynaptic receptors (Burbea et al., 2002). Functional absence of 
UBE3A might thus impair the regulation of GABAA receptors (Dan &Boyd, 2003). In this 
hypothesis, altered regulation of b3 subunit–containing GABAA receptors would lead to 
‘‘compensation’’ involving isoforms of the GABAA receptor that do not contain the b3 
subunit, possibly changing the receptors’ kinetics and desensitization properties. Although 
these changes are expected to be subtle, they may have extensive—but yet undocumented—
effects during brain maturation as well as through the patient’s life. In patients with the 
common 15q11-q13 microdeletion, hemizygosity of GABAA receptor subunits a5, b3, and c3 
has been suggested to underlie deficits in GABA-related neural synchrony mechanisms 
(Egawa et al., 2008). This could explain the propensity for more severe neurologic 
impairment in patients with 15q11-q13 microdeletion. Based on data from human patients 
and animal models, a model of thalamocortical dysfunction resulting from dysregulation of 
synaptic GABAergic neurotransmission has been proposed to account for the typical 
rhythmic EEG features (Dan & Boyd, 2003). In this model, excessive neuronal synchrony 
precludes the generation complex spontaneous activity in neuronal networks and interferes 
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with neuronal responsiveness. Synchronous network activity disrupts processing of inputs 
and, therefore, representation of information. Emergence of cerebellar oscillation in 
maternal Ube3a-deficient mice (Cheron et al., 2005) is consistent with a network mechanism 
implicating gap junctions and GABAA transmission (Dan et al., 2004; Traub et al., 2008). 
This oscillation shows similarities with various mouse models with altered calcium 
signaling (Cheron et al., 2008) and also involves NMDA transmission (Cheron et al., 2005). 
Hippocampal NMDA-dependent long-term potentiation abnormalities have also been 
documented in another model with inactivated maternal Ube3a (Weeber et al., 2003). In 
sum, formation of dendritic spines as well as both synaptic (including GABAA and NMDA 
transmission) and nonsynaptic (including gap junction) influences appear to be specifically 
altered in various brain regions (including hippocampus and cerebellar cortex). But much 
research is still required to fully understand the functional links between lack of UBE3A 
expression and the clinical manifestations of Angelman syndrome. 
10. Perspectives 
Despite the gaps that still preclude comprehensive understanding of Angelman syndrome, 
this condition potentially offers a powerful paradigm for both clinical and basic 
investigation of the complexity of brain maturation and motor, cognitive, and behavioral 
development (Scheiffele & Beg, 2010). Most studies conducted until now have been 
retrospective and based on questionnaires. Such studies have mostly focused on issues 
relating to epilepsy, sleep, behavior, communication, or general health. Although large 
surveys are not expected to provide insights into mechanisms that lead to these 
manifestations, more studies are still required in these areas in order to add to the current 
body of knowledge and to refine the notions that have emerged. Given the trend for 
differences in severity of various phenotypic features between groups of patients from the 
different molecular classes, it would appear critical to carefully record the underlying 
genetic cause when constructing cohorts of patients. This might lead to the delineation of a 
typology of Angelman syndrome with multidimensional classification that could 
accommodate both milder and more severe atypical phenotypes. Studies of more 
homogenous categories thus defined would provide much-needed information about the 
natural history of specific subgroups. They would also make intervention– outcome studies 
more pertinent. Another key issue that has been overlooked in many previous surveys is the 
relationship between phenotypic expression and development. It is essential to take the 
dynamic aspects of development into account. Furthermore, it will become increasingly 
relevant to gather information about aging in Angelman syndrome. Relevant contextual 
factors need to be recognized. Quality-of-life issues need to be addressed. This should also 
encompass the psychological burden on both patients and caregivers, as well as coping 
strategies. Clinical studies could be considerably enhanced if a carefully designed large-
scale database could be set up with open access available to professionals. In this context, 
cross-study evaluation of various features, and their prevalence and natural history could be 
performed reliably. This would also allow assessment of the effect of management 
approaches. In connection with the neurology of Angelman syndrome, epilepsy has been 
the most studied subject. Controlled studies of treatment are still very much needed. Other 
neurologic features would also deserve special attention. With respect to motor control, for 
example, dysfunctions of various components of the motor system, including the motor 
cortex, cerebellum, and basal ganglia, have been hypothesized (Beckung et al., 2004; Dan et 
al., 2001, 2004; Harbord, 2001), but more studies are required to test the hypotheses. It is also  
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important to further investigate cognition. Neuropsychological studies of well-defined 
subgroups of patients are necessary to shed more light on cognitive processing and learning 
strategies. This might have implications on the design of appropriate pedagogic approaches. 
Studies that are more pragmatic are also required, such as those that have assessed training 
programs (Didden et al., 2001). Almost all electrophysiologic studies conducted to date were 
limited to EEG, a number of them entertaining confusion between epileptic and nonepileptic 
changes. Recent methods analyzing brain dynamics and how it modulates neural processing 
can probably yield invaluable information. The typical rhythmic EEG activities likely reflect 
dynamic states of neural circuits. Experimental paradigms could be designed to analyze how 
these network activities are modulated by parameters such as attention or sensory inputs. 
Evoked-potential techniques (Egawa et al., 2008), and, in particular, ‘‘event-related potentials’’ 
will likely provide important information on specific aspects of brain functioning. Studies of 
processing of verbal language will be of special interest. Neuroimaging should also provide 
more insights into Angelman syndrome (Dan et al., 2009). The recent development of new 
analysis paradigms of MRI is likely to have implications in the documentation of alternative 
brain maturation in Angelman syndrome. Functional imaging can address a number of highly 
relevant issues, also including speech processing. There is also a great need for 
neuropathologic studies, as only two autopsies have been published. A large number of 
current studies concern molecular biology, including investigation of the mechanisms of 
imprinting and the possible roles of UBE3A. These studies are extremely important for 
achieving a better understanding of the involved processes. Based on this understanding, 
appropriate modulation might be proposed in order to improve neurologic functioning in 
patients with Angelman syndrome. Molecular biology studies must take into account possible 
differences between studied species. Among the most pressing questions that are yet to be 
solved, it will be crucial to discover the functions of UBE3A that are relevant to Angelman 
syndrome. This might open the way toward possible (partial) compensation for the virtual 
absence of UBE3A where and when it is needed. However, confusion may arise in association 
with the use of terms such as ‘‘cure’’ to characterize reversal of selected abnormalities in rescue 
genetically engineered animal models (Elgersma, 2007). ‘‘Cure’’ implies recovery from an 
illness, which is deceptive in this context. Brain development heavily relies on orderly 
processes that start in the embryo, drawing developmental trajectories. Although the issue of 
neuronal development has been poorly addressed in Angelman syndrome, it is likely to be 
altered given documented impairment in neuronal functioning in patients and animal models. 
Diagnosis is always made relatively late in the brain developmental history: late infancy at best 
and later childhood in most cases. Current research does not aim at discovering a cure but 
rather at improving management in order to optimize development, ameliorate symptoms, 
and improve of quality of life of children and adults with Angelman syndrome. In this context, 
it is important to consider that the effects of lack of UBE3A gene expression may represent an 
emergent property of developmental interactions among a number of brain regions and 
functions at the network level rather than a singular, localized dysfunction in otherwise 
normally developing central nervous system. Given the phenotypic variability even within a 
molecular class, it may prove important to dedicate attention to individuals’ genetic, 
environmental, and/or developmental context as potential modulating factors. Another 
central question concerns the regulation of UBE3A gene expression in the hope that it can be 
enhanced. The phenotypic differences between patients who have one virtually nonfunctional 
copy of the UBE3A gene (i.e., patients with 15q11-q13 microdeletion or UBE3A inactivating 
mutation) and those who have two virtually nonfunctional copies (in case of uniparental 
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disomy or imprinting defect) suggest that there is residual expression when the gene is intact, 
even in the absence of a functional methylation pattern. Although a dietary supplementation 
study did not bring about any clear clinical changes (Bacino et al., 2003), more topical 
intervention might prove useful. Another important question relates to determinants of the 
deleterious effect of absence of other genes in the 15q11-q13 region. This might explain 
phenotypic modulation in cases that are caused by a deletion. It might also point to 
requirements for compensation of lack of gene function. As suggested earlier, the putative 
roles played by GABRB3 may prove to be directly relevant to the function of UBE3A. Some 
studies concentrate on the possible relationship between genes implicated in Angelman 
syndrome and other conditions, such as Rett syndrome, autism, or epileptic syndromes. In 
particular, there seems to be some crucial interactions in the regulation of MECP2 and UBE3A 
expression (Samaco et al., 2005). There have been recent advances in this domain, which 
remain controversial (Jordan & Francke, 2006). If the interactions are confirmed, there are 
likely to be found at multiple levels, perhaps including downstream effects on the regulation 
of the number of neurons, neuronal and synaptic structure or neurotransmission. Therefore, 
these interactions would potentially induce fundamental alterations in network properties of 
the central nervous system. This may also have therapeutic implications.  
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